Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q3 2016 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management conveys already secured demand/business, constraint on counterparties' ability to receive/install/qualify etc, and counterparties working on that now, business ahead. Transcript: Fate Therapeutics. Programs: ProTmune clinical trial, FATE-NK100, ToleraCyte, iPSC platform. Need see if any "demand" already in hand? They are clinical stage, no product revenue except collaboration with Juno. Revenue $1M from Juno collaboration. Is there demand? They have collaboration with Juno, but not described as demand. They have clinical trial enrollment. Maybe "seven U.S. clinical sites are now open for enrollment" - that's about trial sites, not business demand. They are developing products, not selling. The question asks "business or demand that is secured or already arriving" but company is pre-commercial. Could be clinical trial enrollment? No. Need identify if management describes counterparties' ability to receive etc. They mention "Seven U.S. clinical sites are now open for enrollment" - that's their own trial sites, not counterparties. They mention "we continue to engage additional sites for participation in Phase 2" - not demand. Maybe "FATE-NK100 IND filed" and "clinical testing expected to initiate in early 2017" - not demand. No mention of buyers, orders, partners' capacity. So answer NO. Need be careful: The question is about "business or demand" already in hand. In clinical trials, patients? No. Thus NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.